| P2093 | author name string | Fei Liu | |
| | Bei-Sha Tang | |
| | Xiao-Xin Yan | |
| | Jian-Ming Li | |
| | Li-Ling Huang | |
| P2860 | cites work | Purification and cloning of amyloid precursor protein beta-secretase from human brain | Q22010914 |
| | Synapse Formation and Function Is Modulated by the Amyloid Precursor Protein | Q22241520 |
| | sAPP modulates iron efflux from brain microvascular endothelial cells by stabilizing the ferrous iron exporter ferroportin | Q24298395 |
| | Neurotoxicity of Alzheimer's disease Aβ peptides is induced by small changes in the Aβ42 to Aβ40 ratio | Q24298670 |
| | Amyloid beta peptide load is correlated with increased beta-secretase activity in sporadic Alzheimer's disease patients | Q24633400 |
| | Lymphatic Clearance of the Brain: Perivascular, Paravascular and Significance for Neurodegenerative Diseases | Q26753215 |
| | Cysteine proteases as therapeutic targets: does selectivity matter? A systematic review of calpain and cathepsin inhibitors | Q26771736 |
| | Cerebrovascular disease in ageing and Alzheimer's disease | Q26771852 |
| | Axonal transport of APP and the spatial regulation of APP cleavage and function in neuronal cells | Q27022080 |
| | The development of cerebral amyloid angiopathy in cerebral vessels. A review with illustrations based upon own investigated post mortem cases | Q27024753 |
| | APP processing in Alzheimer's disease | Q27694738 |
| | Development and Structural Modification of BACE1 Inhibitors | Q28068099 |
| | Photoactivated gamma-secretase inhibitors directed to the active site covalently label presenilin 1 | Q28139001 |
| | Roles of amyloid precursor protein and its fragments in regulating neural activity, plasticity and memory | Q28202553 |
| | Control of peripheral nerve myelination by the beta-secretase BACE1 | Q28264800 |
| | Assembly, trafficking and function of gamma-secretase | Q28268951 |
| | Cerebral small vessel disease: from pathogenesis and clinical characteristics to therapeutic challenges | Q28287345 |
| | APP is cleaved by Bace1 in pre-synaptic vesicles and establishes a pre-synaptic interactome, via its intracellular domain, with molecular complexes that regulate pre-synaptic vesicles functions | Q28543167 |
| | Alzheimer's disease: the amyloid cascade hypothesis | Q29547160 |
| | APP processing and synaptic function | Q29615873 |
| | The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor | Q29618322 |
| | BACE1, a major determinant of selective vulnerability of the brain to amyloid-beta amyloidogenesis, is essential for cognitive, emotional, and synaptic functions. | Q30483997 |
| | BACE1-/- mice exhibit seizure activity that does not correlate with sodium channel level or axonal localization | Q30496432 |
| | The morphological phenotype of beta-amyloid plaques and associated neuritic changes in Alzheimer's disease | Q30705340 |
| | Cerebral amyloid angiopathy: emerging concepts | Q30894798 |
| | Ischemic brain injury in cerebral amyloid angiopathy | Q30945201 |
| | Sporadic cerebral amyloid angiopathy--an important cause of cerebral haemorrhage in older people | Q31061495 |
| | Physiological Functions of the β-Site Amyloid Precursor Protein Cleaving Enzyme 1 and 2 | Q33575863 |
| | Diagnosis of cerebral amyloid angiopathy. Sensitivity and specificity of cortical biopsy | Q48670233 |
| | Immunoreactivity of presenilin-1 in human, rat and mouse brain | Q48706017 |
| | The relationship between senile plaques and cerebral blood vessels in Alzheimer's disease and senile dementia. Morphological mechanism of senile plaque production. | Q48920129 |
| | Neuronal and nonneuronal quantitative BACE immunocytochemical expression in the entorhinohippocampal and frontal regions in Alzheimer's disease | Q49104487 |
| | Dementia incidence and predictors in cerebral amyloid angiopathy patients without intracerebral hemorrhage. | Q50591685 |
| | The Association of Amyloid-β Protein Precursor With α- and β-Secretases in Mouse Cerebral Cortex Synapses Is Altered in Early Alzheimer's Disease. | Q52147607 |
| | Severely dystrophic axons at amyloid plaques remain continuous and connected to viable cell bodies. | Q52590686 |
| | Amyloid precursor protein in platelets: a peripheral marker for the diagnosis of sporadic AD. | Q53245664 |
| | Amyloid beta 38, 40, and 42 species in cerebrospinal fluid: more of the same? | Q53372046 |
| | Diagnosis of Alzheimer's disease in an exhumed decomposed brain after twenty months of burial in a deep grave. | Q53376435 |
| | Amyloid efflux transporter expression at the blood-brain barrier declines in normal aging. | Q53415989 |
| | Complement interactions with amyloid β1–42: A nidus for inflammation in AD brains | Q58270715 |
| | Immunocytochemical localization of the precursor protein for beta-amyloid in the rat central nervous system | Q67260747 |
| | Distribution of choline acetyltransferase-, serotonin-, dopamine-beta-hydroxylase-, tyrosine hydroxylase-immunoreactive fibers in monkey primary auditory cortex | Q69904541 |
| | NADPH-diaphorase-positive neurons in primate cerebral cortex colocalize with GABA and calcium-binding proteins | Q71160857 |
| | Presenilins are required for gamma-secretase cleavage of beta-APP and transmembrane cleavage of Notch-1 | Q73949956 |
| | Capillary cerebral amyloid angiopathy is associated with vessel occlusion and cerebral blood flow disturbances | Q80932993 |
| | Characteristics of dyshoric capillary cerebral amyloid angiopathy | Q85184310 |
| | Midlife serum cholesterol and increased risk of Alzheimer's and vascular dementia three decades later | Q33621287 |
| | Axonal BACE1 dynamics and targeting in hippocampal neurons: a role for Rab11 GTPase | Q33652469 |
| | Occludin deficiency with BACE1 elevation in cerebral amyloid angiopathy. | Q33654643 |
| | Sortilin Fragments Deposit at Senile Plaques in Human Cerebrum | Q33770251 |
| | Beta-secretase-1 elevation in transgenic mouse models of Alzheimer's disease is associated with synaptic/axonal pathology and amyloidogenesis: implications for neuritic plaque development | Q33849442 |
| | Associations between serum cholesterol levels and cerebral amyloidosis | Q33853002 |
| | An overview of APP processing enzymes and products | Q33927819 |
| | Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease | Q34157492 |
| | β-Secretase-1 elevation in aged monkey and Alzheimer's disease human cerebral cortex occurs around the vasculature in partnership with multisystem axon terminal pathogenesis and β-amyloid accumulation | Q34268487 |
| | Luteinizing hormone, a reproductive regulator that modulates the processing of amyloid-beta precursor protein and amyloid-beta deposition | Q34297011 |
| | Brain endothelial cells produce amyloid {beta} from amyloid precursor protein 770 and preferentially secrete the O-glycosylated form | Q34401049 |
| | Targeting the β secretase BACE1 for Alzheimer's disease therapy | Q34405667 |
| | Lipolysaccharide-Induced Neuroinflammation Is Associated with Alzheimer-Like Amyloidogenic Axonal Pathology and Dendritic Degeneration in Rats | Q34412996 |
| | Distinct sites of intracellular production for Alzheimer's disease A beta40/42 amyloid peptides. | Q34438409 |
| | Chronic temporal lobe epilepsy is associated with enhanced Alzheimer-like neuropathology in 3×Tg-AD mice | Q34479091 |
| | Moving beyond anti-amyloid therapy for the prevention and treatment of Alzheimer's disease | Q34538592 |
| | γ-Secretase is a membrane protein complex comprised of presenilin, nicastrin, aph-1, and pen-2 | Q34648460 |
| | Endothelial nitric oxide modulates expression and processing of amyloid precursor protein | Q34720034 |
| | Structural network alterations and neurological dysfunction in cerebral amyloid angiopathy. | Q34842317 |
| | The evolution of preclinical Alzheimer's disease: implications for prevention trials | Q34849048 |
| | Clearance of amyloid-beta peptide across the blood-brain barrier: implication for therapies in Alzheimer's disease | Q34960461 |
| | Traumatic brain injury precipitates cognitive impairment and extracellular Aβ aggregation in Alzheimer's disease transgenic mice | Q35041065 |
| | Long-term accumulation of amyloid-beta, beta-secretase, presenilin-1, and caspase-3 in damaged axons following brain trauma | Q35103035 |
| | Amyloid-beta transporter expression at the blood-CSF barrier is age-dependent | Q35183396 |
| | Amyloid precursor protein (APP) and beta A4 amyloid in Alzheimer's disease and Down syndrome | Q35417085 |
| | BACE1 elevation is involved in amyloid plaque development in the triple transgenic model of Alzheimer's disease: differential Aβ antibody labeling of early-onset axon terminal pathology | Q35583236 |
| | Non-neuronal and neuronal BACE1 elevation in association with angiopathic and leptomeningeal β-amyloid deposition in the human brain | Q35595669 |
| | The Alzheimer's β-secretase enzyme BACE1 is required for accurate axon guidance of olfactory sensory neurons and normal glomerulus formation in the olfactory bulb | Q35717366 |
| | η-Secretase processing of APP inhibits neuronal activity in the hippocampus | Q35760228 |
| | Cerebral amyloid angiopathy: major contributor or decorative response to Alzheimer's disease pathogenesis | Q35789636 |
| | Experimental microembolism induces localized neuritic pathology in guinea pig cerebrum | Q35793607 |
| | Alzheimer's disease is a vasocognopathy: a new term to describe its nature | Q35841706 |
| | Prion-like spread of protein aggregates in neurodegeneration | Q35946138 |
| | Cerebral amyloid angiopathy and its co-occurrence with Alzheimer's disease and other cerebrovascular neuropathologic changes | Q36037652 |
| | Examining the decomposed brain | Q38266604 |
| | Hemoglobin promotes Abeta oligomer formation and localizes in neurons and amyloid deposits. | Q38333702 |
| | Vascular risk factors and Alzheimer's disease pathogenesis: are conventional pharmacological approaches protective for cognitive decline progression? | Q38357856 |
| | Post-traumatic neurodegeneration and chronic traumatic encephalopathy | Q38372946 |
| | Summary of the evidence on modifiable risk factors for cognitive decline and dementia: A population-based perspective | Q38516632 |
| | The concept of sporadic cerebral small vessel disease: A road map on key definitions and current concepts | Q38695408 |
| | BACE1 Physiological Functions May Limit Its Use as Therapeutic Target for Alzheimer's Disease | Q38718814 |
| | Alzheimer's therapy targeting the β-secretase enzyme BACE1: Benefits and potential limitations from the perspective of animal model studies | Q38812007 |
| | Neuropsychological Effects of Cerebral Amyloid Angiopathy | Q38881022 |
| | Revisiting the peripheral sink hypothesis: inhibiting BACE1 activity in the periphery does not alter β-amyloid levels in the CNS. | Q39139894 |
| | The prion model for progression and diversity of neurodegenerative diseases | Q39151589 |
| | Emerging concepts in sporadic cerebral amyloid angiopathy | Q39196370 |
| | Abnormal platelet amyloid-β protein precursor (AβPP) metabolism in Alzheimer's disease: identification and characterization of a new AβPP isoform as potential biomarker | Q39198550 |
| | The Alzheimer's β-secretase BACE1 localizes to normal presynaptic terminals and to dystrophic presynaptic terminals surrounding amyloid plaques. | Q39755143 |
| | Abnormal accumulation of autophagic vesicles correlates with axonal and synaptic pathology in young Alzheimer's mice hippocampus. | Q40086136 |
| | Validation of Clinicoradiological Criteria for the Diagnosis of Cerebral Amyloid Angiopathy-Related Inflammation | Q40155575 |
| | Regulation of Synaptic Amyloid-β Generation through BACE1 Retrograde Transport in a Mouse Model of Alzheimer's Disease. | Q40350445 |
| | The precision of axon targeting of mouse olfactory sensory neurons requires the BACE1 protease | Q40534733 |
| | The amyloidogenic pathway of amyloid precursor protein (APP) is independent of its cleavage by caspases | Q40800297 |
| | The relationship of amyloid plaques to cerebral capillaries in Alzheimer's disease | Q41215183 |
| | Inhibition of amyloid precursor protein secretases reduces recovery after spinal cord injury | Q42265645 |
| | Confirmation of the amyloidogenic process in posterior cortical atrophy: value of the Aβ42/Aβ40 ratio. | Q43480129 |
| | Increased expression of the amyloid precursor beta-secretase in Alzheimer's disease | Q44060098 |
| | Beta-secretase protein and activity are increased in the neocortex in Alzheimer disease | Q44132132 |
| | Elevated beta-secretase expression and enzymatic activity detected in sporadic Alzheimer disease | Q44270458 |
| | The beta-amyloid-related proteins presenilin 1 and BACE1 are axonally transported to nerve terminals in the brain | Q44760178 |
| | Binding sites of gamma-secretase inhibitors in rodent brain: distribution, postnatal development, and effect of deafferentation. | Q44814697 |
| | Formation of amyloid-beta oligomers in brain vascular smooth muscle cells transiently exposed to iron-induced oxidative stress | Q46120040 |
| | Searching for Neurodegeneration in the Blood of Patients With Alzheimer Disease | Q46878353 |
| | Serial reconstruction of β-protein amyloid plaques: relationship to microvessels and size distribution | Q47405365 |
| | Pharmacological inhibition of BACE1 impairs synaptic plasticity and cognitive functions | Q47685980 |
| | Association of cortical microinfarcts and cerebral small vessel pathology in the ageing brain | Q47900669 |
| | Isolation and characterization of amyloid P component from Alzheimer's disease and other types of cerebral amyloidosis | Q48095732 |
| | Starvation triggers Abeta42 generation from human umbilical vascular endothelial cells | Q48132206 |
| | ADAM10 and BACE1 are localized to synaptic vesicles | Q48143467 |
| | Beta-site amyloid precursor protein cleaving enzyme 1 levels become elevated in neurons around amyloid plaques: implications for Alzheimer's disease pathogenesis | Q48217048 |
| | Release of beta-amyloid from high-density platelets: implications for Alzheimer's disease pathology | Q48219108 |
| | Impaired synaptic plasticity and learning in aged amyloid precursor protein transgenic mice | Q48242315 |
| | Oxidative stress triggers the amyloidogenic pathway in human vascular smooth muscle cells. | Q48270503 |
| | The effect of focal brain injury on beta-amyloid plaque deposition, inflammation and synapses in the APP/PS1 mouse model of Alzheimer's disease. | Q48293839 |
| | Changes with age in the activities of beta-secretase and the Abeta-degrading enzymes neprilysin, insulin-degrading enzyme and angiotensin-converting enzyme | Q48297703 |
| | beta-Secretase expression in normal and functionally deprived rat olfactory bulbs: inverse correlation with oxidative metabolic activity | Q48317897 |
| | Blood brain barrier endothelial cells express candidate amyloid precursor protein-cleaving secretases | Q48349780 |
| | Autopsy at 2 months after death: brain is satisfactorily preserved for neuropathology | Q48438048 |
| | The amyloid protein precursor of Alzheimer's disease is a mediator of the effects of nerve growth factor on neurite outgrowth | Q48458288 |
| | Phases of A beta-deposition in the human brain and its relevance for the development of AD. | Q48567985 |
| | Spinal cord vascular and leptomeningeal amyloid beta-protein deposition in a case with cerebral amyloid angiopathy | Q48572685 |
| | Two types of sporadic cerebral amyloid angiopathy. | Q48661743 |
| | Cerebral Hypoperfusion and the Energy Deficit in Alzheimer's Disease | Q48663991 |
| | Aβ42 production in brain capillary endothelial cells after oxygen and glucose deprivation | Q48664210 |
| | Lithium reduces BACE1 overexpression, β amyloid accumulation, and spatial learning deficits in mice with traumatic brain injury | Q36198046 |
| | Sporadic cerebral amyloid angiopathy: pathology, clinical implications, and possible pathomechanisms. | Q36260752 |
| | BACE1 elevation is associated with aberrant limbic axonal sprouting in epileptic CD1 mice | Q36447042 |
| | Mechanism of cerebral beta-amyloid angiopathy: murine and cellular models | Q36448521 |
| | Amyloid plaque pathogenesis in 5XFAD mouse spinal cord: retrograde transneuronal modulation after peripheral nerve injury | Q36586319 |
| | Dopaminergic innervation of the cerebral cortex: unexpected differences between rodents and primates | Q36649266 |
| | A presenilin dimer at the core of the gamma-secretase enzyme: insights from parallel analysis of Notch 1 and APP proteolysis | Q36690193 |
| | Perivascular neuritic dystrophy associated with cerebral amyloid angiopathy in Alzheimer's disease. | Q36784958 |
| | The role of microglia in amyloid clearance from the AD brain | Q36841789 |
| | Imaging of Cerebral Amyloid Angiopathy with Bivalent (99m)Tc-Hydroxamamide Complexes | Q36903121 |
| | Cerebral β-Amyloid Angiopathy Is Associated with Earlier Dementia Onset in Alzheimer's Disease | Q37025036 |
| | BACE-1 is expressed in the blood-brain barrier endothelium and is upregulated in a murine model of Alzheimer's disease | Q37057708 |
| | Presynaptic dystrophic neurites surrounding amyloid plaques are sites of microtubule disruption, BACE1 elevation, and increased Aβ generation in Alzheimer's disease | Q37099368 |
| | Cerebral amyloid angiopathy and its relationship to Alzheimer's disease. | Q37120270 |
| | Cholesterol as a risk factor for dementia and cognitive decline: a systematic review of prospective studies with meta-analysis | Q37151717 |
| | Blood-brain barrier dysfunction as a cause and consequence of Alzheimer's disease. | Q37216153 |
| | Classification and basic pathology of Alzheimer disease | Q37453000 |
| | CaspNeuroD: a knowledgebase of predicted caspase cleavage sites in human proteins related to neurodegenerative diseases. | Q37544863 |
| | Cerebral amyloid angiopathy: a common cause of cerebral hemorrhage | Q37550702 |
| | Sustained peripheral depletion of amyloid-β with a novel form of neprilysin does not affect central levels of amyloid-β. | Q37556990 |
| | TNF-α regulates the proteolytic degradation of ST6Gal-1 and endothelial cell-cell junctions through upregulating expression of BACE1. | Q37587563 |
| | The beta-secretase enzyme BACE in health and Alzheimer's disease: regulation, cell biology, function, and therapeutic potential | Q37614747 |
| | High plasticity of axonal pathology in Alzheimer's disease mouse models. | Q37630821 |
| | Prion-like mechanisms in neurodegenerative diseases | Q37661351 |
| | Evidence for impaired amyloid β clearance in Alzheimer's disease | Q37690374 |
| | Can BACE1 inhibition mitigate early axonal pathology in neurological diseases? | Q37715869 |
| | Blood-brain-barrier models for the investigation of transporter- and receptor-mediated amyloid-β clearance in Alzheimer's disease | Q37779570 |
| | Sink hypothesis and therapeutic strategies for attenuating Abeta levels | Q37844327 |
| | The physiology of the β-amyloid precursor protein intracellular domain AICD. | Q37961985 |
| | Molecular mechanisms of amyloid oligomers toxicity | Q38005284 |
| | Midlife vascular risk factors and Alzheimer's disease: evidence from epidemiological studies | Q38030399 |
| | β-amyloid deposits in veins in patients with cerebral amyloid angiopathy and intracerebral haemorrhage. | Q38118941 |
| | The mechanical cause of age-related dementia (Alzheimer's disease): the brain is destroyed by the pulse | Q38260491 |
| P433 | issue | 1 | |
| P304 | page(s) | 163 | |
| P577 | publication date | 2017-08-25 | |
| P1433 | published in | BMC Neurology | Q15763734 |
| P1476 | title | Can brain impermeable BACE1 inhibitors serve as anti-CAA medicine? | |
| P478 | volume | 17 | |